# US 2020/0390853 A1 · Active peptide for enhancing the phagocytic functions of retinal pigment epithelium and a use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390853 A1
- Document ID: US20200390853A1
- Status: Published application
- Kind: A1
- Application number: 16/730,251
- Filed: 2019-12-30
- Published: 2020-12-17
- Earliest claimed: 2019-06-14
- Assignees: Beijing Tongren Hospital, Capital Medical University
- Applicants: Beijing Tongren Hospital, Capital Medical University
- Inventors: Jingxue Zhang; Shen Wu; Ningli Wang
- Web page: https://patentgrep.com/patent/US20200390853A1

## CPC

- A61K 38/1709: {from mammals}
- A61K 38/45: Transferases (2)
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure relates to an active peptide for enhancing the phagocytic functions of retinal pigment epithelium and a use thereof, which belongs to the technical field of preparing drugs for treating retinal neurodegenerative diseases. The amino acid sequence of the active peptide for enhancing the phagocytic functions of retinal pigment epithelium described in the disclosure was as shown in SEQ ID NO.1. The active peptide of the present invention has biological characteristics similar to those of Gash full-length proteins, with an effect of enhancing the phagocytic functions of retinal pigment epithelium.

## Claims

### Claim 1

An active peptide for enhancing the phagocytic functions of retinal pigment epithelium, which is characterized in that, the amino acid sequence of the active peptide is as shown in SEQ ID NO.1.

### Claim 2 (depends on 1)

The active peptide of claim 1, which is characterized in that, the nucleotide sequence of the active peptide is as shown in SEQ ID NO.2.

### Claim 3 (depends on 1)

A drug for enhancing the phagocytic functions of retinal pigment epithelium, which is characterized in that, the drug includes the active peptide of claim 1.

### Claim 4 (depends on 2)

A drug for enhancing the phagocytic functions of retinal pigment epithelium, which is characterized in that, the drug includes the active peptide of claim 2.

### Claim 5 (depends on 3)

The drug of claim 3, which is characterized in that, the drug further includes MerTK.

### Claim 6 (depends on 4)

The drug of claim 4, which is characterized in that, the drug further includes MerTK.

### Claim 7 (depends on 1)

A use of the active peptide of claim 1 in preparing drugs for preventing or treating degenerative disease of retina.

### Claim 8 (depends on 2)

A use of the active peptide of claim 2 in preparing drugs for preventing or treating degenerative disease of retina.
